Ovoca Gold PLC (OVXA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ovoca Gold PLC (OVXA) has a cash flow conversion efficiency ratio of -0.067x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-340.00K ≈ $-397.50K USD) by net assets (€5.06 Million ≈ $5.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ovoca Gold PLC balance sheet independence to measure how much of total assets are equity-financed.
Ovoca Gold PLC - Cash Flow Conversion Efficiency Trend (1991–2023)
This chart illustrates how Ovoca Gold PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ovoca Gold PLC (OVXA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Ovoca Gold PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ovoca Gold PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
0.090x |
|
CENTAURUS ENERGY INC.
F:72M0
|
-0.044x |
|
Regent Pacific Properties Inc
V:RPP
|
0.061x |
|
Zephyr Energy PLC
LSE:ZPHR
|
0.043x |
|
Ondine Biomedical Inc
LSE:OBI
|
-3.853x |
|
Maven Income And Growth Vct Plc
LSE:MIG1
|
-0.003x |
|
AOTI Inc
LSE:AOTI
|
-0.280x |
|
Lyra Therapeutics Inc
NASDAQ:LYRA
|
0.566x |
Annual Cash Flow Conversion Efficiency for Ovoca Gold PLC (1991–2023)
The table below shows the annual cash flow conversion efficiency of Ovoca Gold PLC from 1991 to 2023. For the full company profile with market capitalisation and key ratios, see Ovoca Gold PLC (OVXA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €2.50 Million ≈ $2.92 Million |
€1.11 Million ≈ $1.30 Million |
0.446x | +165.91% |
| 2022-12-31 | €7.63 Million ≈ $8.93 Million |
€-5.16 Million ≈ $-6.04 Million |
-0.676x | -107.58% |
| 2021-12-31 | €13.43 Million ≈ $15.70 Million |
€-4.38 Million ≈ $-5.12 Million |
-0.326x | -186.35% |
| 2020-12-31 | €18.55 Million ≈ $21.69 Million |
€-2.11 Million ≈ $-2.47 Million |
-0.114x | -24.99% |
| 2019-12-31 | €23.84 Million ≈ $27.87 Million |
€-2.17 Million ≈ $-2.54 Million |
-0.091x | +33.83% |
| 2018-12-31 | €20.63 Million ≈ $24.11 Million |
€-2.84 Million ≈ $-3.32 Million |
-0.138x | -150.20% |
| 2017-12-31 | €22.40 Million ≈ $26.19 Million |
€-1.23 Million ≈ $-1.44 Million |
-0.055x | -227.60% |
| 2016-12-31 | €23.47 Million ≈ $27.44 Million |
€-394.00K ≈ $-460.63K |
-0.017x | -138.97% |
| 2015-12-31 | €21.45 Million ≈ $25.08 Million |
€924.00K ≈ $1.08 Million |
0.043x | +395.85% |
| 2014-12-31 | €22.46 Million ≈ $26.26 Million |
€-327.00K ≈ $-382.30K |
-0.015x | +86.58% |
| 2013-12-31 | €25.97 Million ≈ $30.37 Million |
€-2.82 Million ≈ $-3.29 Million |
-0.108x | -333.35% |
| 2012-12-31 | €48.62 Million ≈ $56.85 Million |
€2.26 Million ≈ $2.64 Million |
0.046x | -29.58% |
| 2011-12-31 | €50.15 Million ≈ $58.63 Million |
€3.31 Million ≈ $3.87 Million |
0.066x | +52.93% |
| 2010-12-31 | €56.75 Million ≈ $66.34 Million |
€2.45 Million ≈ $2.86 Million |
0.043x | -41.23% |
| 2009-12-31 | €46.42 Million ≈ $54.27 Million |
€3.41 Million ≈ $3.99 Million |
0.073x | +1163.67% |
| 2008-12-31 | €38.20 Million ≈ $44.66 Million |
€222.00K ≈ $259.54K |
0.006x | +117.38% |
| 2007-12-31 | €46.05 Million ≈ $53.84 Million |
€-1.54 Million ≈ $-1.80 Million |
-0.033x | -81.49% |
| 2006-12-31 | €30.83 Million ≈ $36.04 Million |
€-568.00K ≈ $-664.05K |
-0.018x | +57.83% |
| 2005-12-31 | €10.60 Million ≈ $12.39 Million |
€-463.00K ≈ $-541.30K |
-0.044x | +47.88% |
| 2004-12-31 | €4.41 Million ≈ $5.16 Million |
€-370.00K ≈ $-432.57K |
-0.084x | +13.55% |
| 2003-12-31 | €4.48 Million ≈ $5.23 Million |
€-434.00K ≈ $-507.39K |
-0.097x | -3503.35% |
| 2002-12-31 | €3.16 Million ≈ $3.69 Million |
€9.00K ≈ $10.52K |
0.003x | +105.19% |
| 2001-12-31 | €3.39 Million ≈ $3.96 Million |
€-186.00K ≈ $-217.45K |
-0.055x | -14.89% |
| 2000-12-31 | €3.14 Million ≈ $3.67 Million |
€-150.00K ≈ $-175.37K |
-0.048x | +18.22% |
| 1999-12-31 | €3.29 Million ≈ $3.84 Million |
€-192.00K ≈ $-224.47K |
-0.058x | +45.56% |
| 1998-12-31 | €3.29 Million ≈ $3.85 Million |
€-353.00K ≈ $-412.69K |
-0.107x | -325.41% |
| 1997-12-31 | €2.18 Million ≈ $2.55 Million |
€-55.00K ≈ $-64.30K |
-0.025x | +22.55% |
| 1996-12-31 | €1.93 Million ≈ $2.26 Million |
€-63.00K ≈ $-73.65K |
-0.033x | -2823.60% |
| 1994-12-31 | €1.79 Million ≈ $2.10 Million |
€-2.00K ≈ $-2.34K |
-0.001x | +96.94% |
| 1993-12-31 | €1.87 Million ≈ $2.18 Million |
€-68.00K ≈ $-79.50K |
-0.036x | -471.51% |
| 1992-12-31 | €1.12 Million ≈ $1.31 Million |
€11.00K ≈ $12.86K |
0.010x | +122.88% |
| 1991-12-31 | €1.12 Million ≈ $1.31 Million |
€-48.00K ≈ $-56.12K |
-0.043x | -- |
About Ovoca Gold PLC
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health. It's lead product is BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporate… Read more